|Demographics||Relapsing-remitting MS||Secondary progressive MS||All MS||Controls|
|Mean age, years (SD)||40.3 (13.9)||55.3 (9.3)||42.2 (13.3)||34.3 (11.0)|
|Extended Disability Status Scale range/median/SD||0–4.5/3/1.3||4–6.5/6/1.3||0–6.5/3/1.7||/|
|Disease duration, years, range/mean/SD||1–35/11.2/10.2||11–36/23/12.5||1–36/13.1/11.1||/|
|Patients on medication, no||15/17||3/3||18/20||/|
|Patients on natalizumab, no/total||10/15||0||10/20||/|
|Relapses*, no, range/mean/SD||0–4/0.9/1.1||0||0–4/0.9/1.1||/|
|CSF positive†, no/total||16/17||3/3||19/20||/|
|MRI positive‡, no/total||17/17||3/3||20/20||/|
- Research paper
The perfect crime? CCSVI not leaving a trace in MS
Visit the full archive of podcasts for JNNP here >>
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.